Twinbeech Capital LP Makes New Investment in Zoetis Inc. (NYSE:ZTS)

Twinbeech Capital LP bought a new position in shares of Zoetis Inc. (NYSE:ZTS - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm bought 126,300 shares of the company's stock, valued at approximately $20,578,000.

Other large investors also recently bought and sold shares of the company. Callahan Advisors LLC lifted its holdings in Zoetis by 90.4% during the 4th quarter. Callahan Advisors LLC now owns 13,105 shares of the company's stock worth $2,135,000 after buying an additional 6,221 shares during the last quarter. CIBC Asset Management Inc lifted its holdings in Zoetis by 24.1% during the 4th quarter. CIBC Asset Management Inc now owns 237,369 shares of the company's stock worth $38,617,000 after buying an additional 46,050 shares during the last quarter. Schroder Investment Management Group lifted its holdings in shares of Zoetis by 2.6% in the 4th quarter. Schroder Investment Management Group now owns 245,726 shares of the company's stock worth $40,036,000 after purchasing an additional 6,169 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of Zoetis by 0.3% in the 4th quarter. Vanguard Group Inc. now owns 41,366,877 shares of the company's stock worth $6,739,905,000 after purchasing an additional 120,158 shares during the last quarter. Finally, Alberta Investment Management Corp lifted its holdings in shares of Zoetis by 2,050.0% in the 4th quarter. Alberta Investment Management Corp now owns 30,100 shares of the company's stock worth $4,904,000 after purchasing an additional 28,700 shares during the last quarter. Institutional investors own 92.80% of the company's stock.

Zoetis Stock Up 1.7%

Shares of Zoetis stock opened at $163.03 on Monday. Zoetis Inc. has a 1-year low of $139.70 and a 1-year high of $200.33. The company has a market capitalization of $72.58 billion, a P/E ratio of 29.80, a PEG ratio of 2.78 and a beta of 0.94. The business's fifty day moving average price is $156.46 and its two-hundred day moving average price is $165.22. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.75 and a quick ratio of 1.08.

Zoetis (NYSE:ZTS - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The company reported $1.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.40 by $0.08. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The company had revenue of $2.22 billion for the quarter, compared to analysts' expectations of $2.20 billion. During the same period last year, the firm earned $1.38 EPS. The firm's revenue for the quarter was up 1.4% on a year-over-year basis. As a group, research analysts forecast that Zoetis Inc. will post 6.07 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on ZTS shares. Piper Sandler raised their price target on Zoetis from $205.00 to $210.00 and gave the stock an "overweight" rating in a report on Monday, May 12th. Barclays raised their price target on Zoetis from $242.00 to $244.00 and gave the stock an "overweight" rating in a report on Friday, February 14th. StockNews.com raised Zoetis from a "hold" rating to a "buy" rating in a report on Friday, March 7th. Morgan Stanley cut their price target on Zoetis from $243.00 to $238.00 and set an "overweight" rating on the stock in a report on Friday, February 14th. Finally, UBS Group cut their price target on Zoetis from $189.00 to $170.00 and set a "neutral" rating on the stock in a report on Wednesday, May 7th. One analyst has rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Buy" and an average price target of $212.75.

Insider Activity

In other news, EVP Roxanne Lagano sold 326 shares of Zoetis stock in a transaction on Monday, March 10th. The stock was sold at an average price of $170.00, for a total transaction of $55,420.00. Following the transaction, the executive vice president now directly owns 15,781 shares in the company, valued at approximately $2,682,770. This trade represents a 2.02% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Willie M. Reed sold 1,210 shares of Zoetis stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total value of $201,029.40. Following the transaction, the director now owns 11,245 shares in the company, valued at approximately $1,868,244.30. This trade represents a 9.71% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.18% of the stock is owned by insiders.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.